At 10:18 am on March 9, 2022, Shanghai, China, Zencore Biologics held the second R&D and production project in the "Life Blue Bay" in Lin-gang New Area, Shanghai.

It's marks that Zencore Biologics has stepped to a new level on a new journey and another step forward on the road of internationalization.

In order to better meet the increasing production capacity needs of domestic and international customers, Zencore will invest more than 1.3 billion RMB to build a 66,000㎡ commercial production base in Lin-gang and 150 million RMB to build the ADC production plant, on top of the 150 million RMB invested in the Lin-gang pilot plant (4x200L, 1x500L) which is already in operation.

Zencore Biologics R&D and Production Project Phase II covers a total area of about 5,670㎡, including the global R&D center, analysis and testing center, new technology development center and other facilities. The area is about 5,775.85㎡.

Jianxin Chen, Chairman and CEO of Zencore Biologics, said:"I am very pleased that Zencore Biologics R&D and production project phase II has started today. At the same time, I would like to thank people from all walks of life for their participation and attention to the company and this project. Since its establishment in 2017, Zencore Biologics has always adhered to the values of "Customer Focus, Quality Oriented", we will cooperate with domestic and foreign biopharmaceutical companies to develop and produce high-quality biological drugs. The first phase of Zencore Biologics Lin-gang commercial production project is about to be completed, with a total of 3x2,000L disposable production lines and 3x5,000L stainless steel production lines, Zencore Biologics R&D and production project phase II will continue to build supporting facilities such as production, R&D and quality inspection complex, analysis and testing center, new technology development center, which is not only the key foundation for the company to achieve the next stage of development goals, but also an important step for Zencore to help the development of global biopharmaceutical enterprises."

Since its establishment in November 2017, Zencore Biologics has undertaken more than 200 projects and provided technical services to nearly 100 domestic and foreign biopharmaceutical companies. Among them, it has assisted customers in completing 8 IND applications and obtaining clinical approvals.